Small-scale clinical trials have provided encouraging evidence on the short-term orexigenic effects of subcutaneous ghrelin administration in malnourished dialysis patients. New treatment strategies to tackle the excess mortality of this patient group are urgently needed, but the strengths, shortcomings and unanswered questions related to ghrelin treatment need to be highlighted.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Carrero, J. J. Identification of patients with eating disorders: clinical and biochemical signs of appetite loss in dialysis patients. J. Ren. Nutr. 19, 10–15 (2009).
Wynne, K. et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized placebo-controlled trial. J. Am. Soc. Nephrol. 16, 2111–2118 (2005).
Ashby, D. R. et al. Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney Int. 76, 199–206 (2009).
Asakawa, A. et al. Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 54, 18–24 (2005).
Rodriguez Ayala, E. et al. Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Nephrol. Dial. Transpl. 19, 421–426 (2004).
Ashitani, J.-I., Matsumoto, N. & Nakazato, M. Ghrelin and its therapeutic potential for cachectic patients. Peptides doi: 10.1016/j.peptides.2009.07.002
Yoshimoto, A. et al. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J. Am. Soc. Nephrol. 13, 2748–2752 (2002).
Nagaya, N. et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110, 3674–3679 (2004).
DeBoer, M. D. et al. Ghrelin treatment of chronic kidney disease: Improvements in lean body mass and cytokine profile. Endocrinology 149, 827–835 (2008).
Murata, M. et al. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J. Biol. Chem. 277, 5667–5674 (2002).
Vestergaard, E. T. et al. Ghrelin infusion in humans induces acute insulin resistance and lipolysis independent of growth hormone signaling. Diabetes 57, 3205–3210 (2008).
Barazzoni, R. et al. Higher total ghrelin levels are associated with higher insulin-mediated glucose disposal in non-diabetic maintenance hemodialysis patients. Clin. Nutr. 27, 142–149 (2008).
Theander-Carrillo, C. et al. Ghrelin action in the brain controls adipocyte metabolism. J. Clin. Invest. 116, 1983–1993 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Carrero, J., Stenvinkel, P. Can ghrelin improve appetite in uremic wasting?. Nat Rev Nephrol 5, 672–673 (2009). https://doi.org/10.1038/nrneph.2009.171
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2009.171
This article is cited by
-
Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients
Kidney International (2011)
-
Like total ghrelin, acylated ghrelin is also lower in HD patients with cardiovascular disease
Kidney International (2011)
-
Association with Helicobacter pylori infection and ghrelin level in hemodialysis patients
Kidney International (2011)
